Stockscreener 앱 받기
5.285
2.42%
0.125
Entrada Therapeutics Inc 주식(TRDA)의 최신 뉴스
Real time breakdown of Entrada Therapeutics Inc. stock performanceWeekly Trading Summary & Stock Portfolio Risk Management - Newser
Applying chart zones and confluence areas to Entrada Therapeutics Inc.IPO Watch & Weekly Chart Analysis and Trade Guides - Newser
Tools to assess Entrada Therapeutics Inc.’s risk profilePortfolio Gains Summary & Accurate Trade Setup Notifications - Newser
Is Entrada Therapeutics Inc. stock reversal real or fakeJuly 2025 Closing Moves & Safe Swing Trade Setup Alerts - Newser
Entrada Therapeutics Inc. recovery potential after sell offFree Long Hold Safe Return Strategy - Newser
How Entrada Therapeutics Inc. stock performs during market volatilityFree Accurate Buy Point for Momentum Stocks - Newser
Is Entrada Therapeutics Inc. meeting your algorithmic filter criteriaSmart Stock Forecast Using AI Algorithms - Newser
What makes Entrada Therapeutics Inc. stock price move sharplyTrading Opportunities Forecast by AI Insight - Newser
Measuring Entrada Therapeutics Inc.’s beta against major indicesBuy and Hold Position Summary Review - Newser
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's Estimates - 富途牛牛
HC Wainwright Issues Pessimistic Outlook for TRDA Earnings - Defense World
Roth Capital Issues Pessimistic Forecast for TRDA Earnings - Defense World
Why Entrada Therapeutics Inc. stock attracts strong analyst attentionWeekly Market Direction and Sector Summary - Newser
William Blair Issues Negative Forecast for TRDA Earnings - Defense World
Is Entrada Therapeutics Inc. stock bottoming outFree AI Screening for Swing Trade Picks - Newser
Entrada Therapeutics' Revenue Estimates Cut by 57% Amid Weaker Q1 Results - AInvest
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Are Cutting Their Estimates: Here's What You Need To Know - uk.finance.yahoo.com
Entrada Therapeutics (NASDAQ:TRDA) Downgraded to Sell Rating by Wall Street Zen - Defense World
Live market analysis of Entrada Therapeutics Inc.Market Stability and Long-Term Growth Outlook - Newser
Sentiment analysis tools applied to Entrada Therapeutics Inc.Algorithmic Forecast for Swing Trading Picks - Newser
Roth/MKM lowers Entrada Therapeutics stock price target to $17 from $21 - Investing.com Canada
Buy Rating for Entrada Therapeutics: Strong Pipeline and Financial Stability Amidst DMD Advancements - TipRanks
Entrada Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Entrada (TRDA) Q2 Revenue Drops 98% - AOL.com
Entrada Therapeutics 2025 Q2 Earnings Misses Targets with Net Loss Widens 178.3% - AInvest
Entrada Therapeutics Reports Q2 2025 Financial Results - TipRanks
Entrada Therapeutics Q2 Revenue Falls 98%, Losses Widen to $1.04 per Share - AInvest
Entrada (TRDA) Q2 Revenue Drops 98% - The Motley Fool
Entrada Therapeutics shares fall 1.01% after-hours after reporting a net loss of USD 43.1 million for Q2 2025. - AInvest
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates - sharewise.com
Entrada Therapeutics Reports Q2 Loss, Misses Revenue Estimates, Shares Down 66.3% YTD - AInvest
Entrada Therapeutics August 2025 slides: advancing four clinical-stage programs - Investing.com Canada
Entrada Therapeutics earnings missed by $0.22, revenue fell short of estimates - Investing.com Canada
Entrada Therapeutics, Inc. SEC 10-Q Report - TradingView
Entrada Therapeutics Q2 collaboration revenue drops, net loss widens - MarketScreener
Entrada Therapeutics Reports Second Quarter 2025 Financial Results - Stock Titan
Promising Clinical Developments and Strategic Pipeline Expansion Support Buy Rating for Entrada Therapeutics - TipRanks
Can volume confirm reversal in Entrada Therapeutics Inc.Pattern Recognition Based Market Move Prediction - Newser
0.62%
자본화:
|
볼륨(24시간):